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INPATIENT BURDEN OF ILLNESS AND PREDICTORS OF CHARGES OR 
LENGTHS OF STAY AMONG ADULT HEART TRANSPLANTATION
PATIENTS
Olvey EL, Skrepnek GH
University of Arizona, Tucson, AZ, USA
OBJECTIVES: To assess the role of hospital, patient, payer and clinical factors 
on inpatient hospital lengths of stay (LOS) and total charges in adults undergoing 
heart transplantation. METHODS: This analysis utilized the nationally representative 
inpatient hospital discharge records from the Agency for Healthcare Research and
Quality (AHRQ) Healthcare Cost and Utilization Project (H-CUP) Nationwide
Inpatient Sample (NIS) from 2002 to 2005. All patients above 18 years of age
receiving a heart transplantation procedure were selected for inclusion. Speciﬁ c vari-
ables of interest included patient demographics (e.g., age, sex, race, income), hospital
characteristics (e.g., rural/urban), payer (e.g., Medicare, commercial, uninsured), 
procedures, diagnoses, case-mix risk adjustment (e.g., all patient reﬁ ned DRG (APR-
DRG)), and inpatient mortality. Outcomes analyzed were LOS and total charges. 
Gamma and negative binomial generalized linear models with log-links were employed 
with an a priori alpha of 0.05 for statistical signiﬁ cance. Human subjects approval 
was obtained from the University of Arizona. RESULTS: Overall, 5911 patients
underwent a heart transplantation between 2002–2005, with 74.1% of these patients
being males. Mean charges were $332,617 o $212,403. Average LOS was 41.76 o
50.16 days. Inpatient mortality was 5.4%. Regression analyses indicated signiﬁ cant 
associations between charges and number of procedures (Incidence Rate Ratio (IRR) 
 1.074, 95% CI  1.059–1.089), inpatient mortality (IRR  1.274, 95% CI 
1.094–1.483), APR-DRG (IRR  1.126, 95% CI  1.061–1.195), African-American 
race (IRR  0.871, 95% CI  0.783–0.969), and hospital location (IRR small metro-
politan  0.799, 95% CI  0.731–0.874, IRR micropolitan/rural  0.741, 95% 
CI  0.661–0.831). These analyses also indicated signiﬁ cant associations between LOS 
and number of diagnoses (IRR  0.979, 95% CI  0.960–0.997), number of proce-
dures (IRR  1.104, 95% CI  1.082–1.126), APR-DRG (IRR  1.291, 95% CI 
1.136–1.467), and hospital location (IRR micropolitan/rural  0.779, 95% CI 
0.635–0.958). CONCLUSIONS: This investigation of 5911 adult heart transplant 
patients suggests that several factors are signiﬁ cantly associated with LOS and charges. 
Continued research, particularly subgroup analyses and long term follow-up, are
warranted.
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ECONOMIC BURDEN OF ATHEROSCLEROSIS AMONG PATIENTS WITH
TYPE-2 DIABETES MELLITUS
Ohsfeldt RL1, Gandhi SK2, Fox KM3, Bullano M2
1Texas A & M Health Science Center, College Station, TX, USA, 2AstraZeneca, LP, Wilmington, 
DE, USA, 3University of Maryland School of Medicine, Monkton, MD, USA
OBJECTIVES: The present study estimated cardiovascular event rates and direct
medical costs attributable to the medical management of type-2 diabetes mellitus 
(T2DM) patients with diagnosed atherosclerosis. METHODS: Using national admin-
istrative claims data, the number of cardiovascular (CV) events (i.e., myocardial 
infarction, stroke, revascularization) and direct costs of care were quantiﬁ ed among
patients 17 years of age with T2DM and, with or without an ICD-9 diagnostic 
code for coronary or cerebral atherosclerosis between January 1, 2002 and December
31, 2004. Patients with a CV event in the 12 months prior to index date were excluded. 
A comparison cohort (n  14,188) with T2DM and no atherosclerosis diagnosis
was matched on age, gender, geography, and Charlson comorbidity score to patients 
with diagnosed atherosclerosis and T2DM (n  10,842). Differences between patient 
groups were tested for CV event rates per 1000 patients and monthly costs for 
12 months pre- and post-diagnosis. RESULTS: The cohorts included 55% men 
with a mean age of 60.5 years (30% were   65 years of age). Patients with 
atherosclerosis and T2DM had 239 CV events/1000 patients and the comparison 
cohort with T2DM had 39.8/1000 patients at 12 months post-index date, p  0.01. 
Mean total cost of care for patients with atherosclerosis and T2DM was $10,039 
for the 12 months before and $18,371 for 12 months post-diagnosis, an 83% 
increase. One-year post-index total costs were signiﬁ cantly higher among atheroscle-
rosis and T2DM patients than the comparison cohort ($18,371 vs. $5,765, p  0.01). 
The attributable cost (difference between atherosclerosis pre- and post costs and 
comparison pre- and post costs) for atherosclerosis was $627 per month ($7524 
for 1 year). CONCLUSIONS: Patients with diagnosed atherosclerosis and T2DM
have substantial medical and economic burden attributable to their atherosclerosis. 
Utilizing administrative data, health plans may identify these patients for more effec-
tive management and treatment of their underlying atherosclerosis to reduce this
burden.
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MANAGEMENT OF PRIMARY ATRIAL FIBRILLATION (AF): 
PATIENT CHARACTERISTICS AND HOSPITAL CARE SETTING
Spalding JR1, Exuzides A2, Colby C2, Neil N2, Noe L2
1Astellas Pharma US, Inc., Deerﬁ eld, IL, USA, 2ICON Clinical Research, San Francisco, CA, 
USA
OBJECTIVES: To describe and differentiate characteristics and costs of patients 
admitted for treatment of primary AF in hospital emergency department (ED) and
inpatient settings. METHODS: Analysis of 2004–2005 discharges from the Premier 
Perspective database, including patients with primary AF diagnoses and evidence of 
initial therapy with electric conversion (EC) or an IV antiarrhythmic (amiodarone,
ibutilide or procainamide). RESULTS: Of 11108 discharges evaluated, 34% were 
admitted directly as inpatients and 66% presented to the ED. Of these, 14% were 
treated and released from the ED; the remaining 86% were transferred to the inpatient 
setting. ED patients were signiﬁ cantly (p  0.0001) younger with fewer comorbidities 
(p  0.0001) than either transfer or direct admit patients. Initial conversion therapy 
for the vast majority (79%) of ED treated patients was either EC or ibutilide, both of 
which are fast acting. Only 10% of ED patients received initial amiodarone. In con-
trast, 52% (42%) of transfer (direct) patients were treated with initial amiodarone 
and 39% (54%) received initial EC or ibutilide. About 4% of ED patients required a 
second conversion attempt compared to 13% of inpatient discharges. Median LOS 
was 4 days for both direct admit and transfer patients. Average costs were highest
among direct admit ($9229) vs. transfer ($8811) and ED ($1209) patients (p 
0.0001). CONCLUSIONS: Health care resource utilization is high for patients pre-
senting with acute AF and varies signiﬁ cantly by hospital care setting. Adjusted 
average costs of treating primary AF in the inpatient setting are signiﬁ cantly higher 
than the costs of treatment in the ED. Patient characteristics and selected method of 
cardioversion may impact both choice of care setting and costs. In clinically appropri-
ate patients, the availability of fast-acting conversion therapies suitable for use in the 
ED may obviate the need for inpatient admission and, thus, reduce the health care
burden of treating AF in the US.
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INPATIENT RESOURCE USE AMONG PATIENTS TREATED FOR PRIMARY
ATRIAL FIBRILLATION (AF): ROLE OF CLINICAL FACTORS AND CHOICE
OF INITIAL CONVERSION THERAPY
Spalding J1, Exuzides A2, Colby C2, Neil N2, Noe L2
1Astellas Pharma US, Inc., Deerﬁ eld, IL, USA, 2ICON Clinical Research, San Francisco, CA, 
USA
OBJECTIVES: Prior analyses showed that AF patients treated with initial IV
amiodarone had signiﬁ cantly higher adjusted average resource use compared 
with other therapies. This analysis assesses whether these results can be explained 
by presence of classic AF covariate (AFC) diagnoses (heart failure; peripheral vascular
disease). METHODS: We used 2004–05 discharges from the Premier Perspective
database, including patients with primary AF diagnoses and evidence of initial 
therapy with electric conversion (EC) or an IV antiarrhythmic [amiodarone (AM), 
ibutilide (IB) or procainamide (PR)]. Patients were classiﬁ ed by AFC status. Inpatient 
costs and LOS were adjusted for clinical, demographic and hospital factors. RESULTS:
We stratiﬁ ed 10048 discharges into groups with AFC (28%) and without. Results 
showed that patients with AFC had higher costs (p  .0001) and longer LOS overall 
(p  .0001) and were 34% more likely to be treated with initial AM (p  .0001) vs. 
patients without, thus explaining some of the differences observed earlier. However,
resource use with initial AM remained signiﬁ cantly higher than with any other 
initial therapy regardless of patients’ AFC status. Among those without AFC,
adjusted average costs were $440$1988 higher (p  .0001) and LOS was 0.4–1 
day longer (p  .0001) with initial AM than with any other initial therapy. Among
patients with AFC, initial AM was $1602–$3266 higher (p  .0001) and LOS 
was 1.1–1.5 days longer (p  .005) than with any other initial therapy. CONCLU-
SIONS: There are signiﬁ cant inpatient cost and LOS differences among AF patients
depending on initial therapy and presence of AFC. Patients with AFC had higher 
adjusted average costs and LOS than those without and were more likely to be treated
with initial AM. However, adjusted average costs and LOS were highest among 
patients treated with initial AM regardless of AFC status. Further research should 
explore whether factors such as time to conversion affect resource use among these
patients.
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COST AND OUTCOMES AFTER FIRST ACUTE MYOCARDIAL
INFARCTION: STUDY ON 12049 INDIVIDUALS USING
ADMINISTRATIVE DATABASES
Mantovani LG1, Fornari C2, Madotto F2, Riva M2, Chiodini V2, Ferrario M3, Merlino L4, 
Zocchetti C4, Cesana G2
1University Federico II, Naples, Italy, 2University of Milano-Bicocca, Monza, Lombardia, Italy, 
3University of Insubria, Varese, Lombardia, Italy, 4Lombardy Region, Milano, Italy
OBJECTIVES: To estimate the economic burden of AMI incident events registered 
in 2003 in Lombardy, the most inhabited region of Italy. METHODS: Data were 
extracted from health care administrative databases of Lombardy Region, which 
covers a population of about 9.2 million members. Administrative Healthcare 
databases related to eligibility criteria, hospital admissions (HA), pharmaceutical 
and outpatient claims of Lombardy Region citizens have been organized, using pro-
babilistic record linkage, in a data warehouse, called DENALI, to facilitate processing
and analysis. Using DENALI, we conducted a longitudinal and naturalistic study
on the burden of incident AMI in the perspective of the regional health service
(RHS). We identiﬁ ed all individuals with a HA for incident AMI (ICD-9-CM 
codes 410.xx, excluding codes 410.x2) during the year 2003 and followed them up 
to dec.31st 2005, death or transfer. We used charges to the RHS to quantify the 
economic burden of AMI to the RHS. Outcomes were quantiﬁ ed in term of morbidity
(sequelae) and mortality. We report on cost (overall and monthly cost-per-patient) and 
mortality. RESULTS: During 2003, 12,049 individuals (64% males, mean age 70
/13 y.o.) had a HA for incident AMI. A total of 3380 (28%) subjects died during 
an average follow-up period of 23 months. The total cost for all patients during the
ﬁ rst year was €163 million, corresponding to the 1% of the health care budget of 
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Lombardy. The monthly cost in the ﬁ rst year was €1249 per person (77% attributable 
to HAs, 15% to pharmaceuticals and 8% to outpatient claims), decreasing to 
€309 in the following years (54% HAs, 31% pharmaceuticals, 16% outpatient).
CONCLUSIONS: This large study on the burden of AMI shows the epidemiologic,
economic and clinical impact of the disease. DENALI, with its large population 
followed over time is a powerful and dynamic tool for epidemiologic and health
economic research.
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ADMINISTRATIVE CLAIMS IN A LARGE BRAZILIAN NATIONWIDE 
DATABASE: A DESCRIPTIVE ANALYSIS OF THE DIRECT MEDICAL COSTS
OF CORONARY ARTERY BYPASS GRAFTING (CABG) AMONG
DIFFERENT REGIONS IN A CONTINENTAL-SIZE COUNTRY
Fonseca MCM1, Abicalaffe CL2, Muranaka AH3, Araujo GT1
1UNIFESP – Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2Impacto
Tecnologias Gerenciais em Saude, Curitiba, Parana, Brazil, 3Universidade Federal de São
Paulo, Sao Paulo, SP, Brazil
OBJECTIVES: Acute coronary syndromes (ACS) are life-threatening disorders 
requiring intensive medical management or invasive cardiovascular procedures. CABG 
is an important therapeutic procedure among these patients. In Brazil almost 21,000 
CABG are performed in public hospitals costing the government R$7379.49 each in 
average. The aim of this study is to determine the direct medical costs of CABG among
different Brazilian regions in the private setting. METHODS: Retrospective single-
cohort study analyzed administrative claims data for patients with ACS submitted to 
CABG in 2007–2008. From a nationwide database with 1,801,344 people all the
patients with ACS submitted to CABG were selected. The patients were split according 
to the Brazilian geographical region where the procedure was performed. Student T 
test was used to compare the costs among three different regions. RESULTS: We 
identiﬁ ed 263 patients with ACS submitted to CABG. 67% of the procedures 
were performed in Southeast (SE) region, 25% in Middle West (MW) and 8% in the
south region. The average o SD, quartile 25%, median and 75% of the CABG cost 
of whole sample were R$15,849.72 o R$7,355.69, R$12,153.84, R$14,605.45 and
R$18,735.46, respectively. The same parameters for the SE, MW and S regions were,
respectively R$15,721.25oR$8,309.74, R$11,545.23, R$14,398.47 and R$18,657.87; 
R$16,744.15 o R$4,212.57, R$13,340.56, R$15,688.26 and R$19,325.96 and
R$14,035.03 o R$6,272.96, R$9,145.53, R$14,163.88 and R$17,103.31. There was 
no statistical difference among the different regions of Brazil of total CABG cost. There
was no statistical difference among the different regions and the total sample average.
CONCLUSIONS: The CABG average cost we found represent the average Brazilian
private setting health cost independent of the region studied. The average total CABG 
cost in the private setting is at least the double in relation to the average total CABG 
cost in the public setting.
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A CONCEPTUAL ANALYSIS OF THE COSTS OF CARE FOR A “MAJOR
BLEED” IN STUDIES OF ANTIPLATELET AND ANTITHROMBOTIC
THERAPIES
Harshaw Q1, Frye C1, Hauch O2
1EPI-Q, Inc., Oak Brook, IL, USA, 2AstraZeneca, LP, Wilmington, DE, USA
OBJECTIVES: Antiplatelet and antithrombotic therapies have long been the focus of 
extensive clinical and economic investigations. In many of these studies, the primary 
endpoint of analysis was the incidence of “major bleeding.” Unfortunately, major 
bleeding does not have a standard or universal deﬁ nition. Major cardiovascular studies 
such as GUSTO, CURE, TIMI and the International Society on Thrombosis and 
Haemostasis (ISTH) have each established deﬁ nitions that result in vastly different
outcomes. Additionally, none of the common deﬁ nitions were designed for patients
undergoing surgery as part of their care. Analyses that compare outcomes from mul-
tiple trials must carefully examine the deﬁ nitions used. METHODS: We analyzed the
effect of applying 6 major bleeding deﬁ nitions on the incidence and costs of care for 
acute coronary syndrome (ACS) patients undergoing coronary artery bypass graft 
surgery (CABG) in their index hospitalization in a previously developed database of 
ACS patients from 14 health systems across the United States. RESULTS: Our com-
parison found that application of the different deﬁ nitions could result in a large 
variance in the primary outcome of “major bleeding” with equal impact on the com-
parisons for the cost of care. The incidence of major bleeding varied by as much as
50% as did the cost of treatment. The data review included ACS patients who under-
went CABG between January 2005 and December 2006. CONCLUSIONS: Compar-
ing the incidence, impact and costs of treating major bleeding between various clinical 
trials requires a careful assessment of the deﬁ nitions used. Development of a single 
standard deﬁ nition of “major bleeding” for use in clinical and observational trials is
recommended.
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COST-EFFECTIVENESS OF EZETIMIBE/SIMVASTATIN VERSUS
SIMVASTATIN: WILL THE INCREASED RISK OF CANCER MAKE
EZETIMIBE/SIMVASTATIN AN INAPPROPRIATE TREATMENT CHOICE?
Wang CC, Biddle AK, Farley JF
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: Although ezetimbe/simvastatin (10/40 mg/day) combination therapy
may have a superior cholesterol-lowering proﬁ le and be more cost effective than statin 
monotherapy, recent data suggest an increased risk of cancer. We estimate the cost-
effectiveness of ezetimibe/simvastatin vs. simvastatin (40 mg/day) monotherapy, evalu-
ating the effect of this risk. METHODS: A Markov model, employing a 1-year cycle,
was employed to estimate the incremental cost, outcomes, and cost-effectiveness ratio
(ICER) over a 5-year time horizon. Efﬁ cacy data were obtained from the Simvastatin 
and Ezetimibe in Aortic Stenosis (SEAS) study, the Scandinavian Simvastatin Survival 
Study, and the Heart Protection Study. Costs were estimated from fee schedules,
diagnosis-related groups, and average wholesale prices. Utility weights were obtained 
from the peer-reviewed literature. All costs and outcomes after the ﬁ rst year were dis-
counted 3% annually in the base-case. Deterministic and probabilistic sensitivity 
analyses were conducted to evaluate the effect of parameter uncertainty and assump-
tions on the model results. A cost-effectiveness acceptability curve displays the prob-
ability that ezetimibe/simvastatin is cost effective. RESULTS: Ezetimibe/simvastatin 
was dominant (i.e., cost less, resulted in better outcomes) in the base-case scenario. 
For a 1 million-patient cohort, ezetimibe/simvastatin would cost $1,674,715,503 less 
than monotherapy and would result in 15,906 additional quality-adjusted life-years
(QALYs). One-way sensitivity analyses indicate that higher incidence of cancer, lower 
monotherapy costs, and higher risk of myocardial infarction (MI) reduce the cost-
effectiveness of ezetimibe/simvastatin substantially. According to probabilistic analy-
ses, ezetimibe/simvastatin is cost-effective at $50,000/QALY only 36.7% of the time; 
even at a willingness-to-pay of $100,000/QALY, ezetimibe/simvastatin is cost effective
less than 50% of the time. CONCLUSIONS: Although our study suggests that simv-
astatin/ezetemibe treatment is cost effective, policy makers should interpret these 
results in light of possible uncertainty surrounding the incidence of cancer, incidence
of myocardial infarction, and the true cost of simvastatin treatment following generic 
approval.
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COST-EFFECTIVENESS ANALYSIS OF ADD-ON ALISKIREN TO LOSARTAN 
TREATMENT FOR PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION
AND NEPHROPATHY IN THE CZECH PATIENTS FROM PAYOR
PERSPECTIVE
Kutscherauer P1, Kodym R2, Bartaskova D3
1Novartis Pharmaceuticals Corporation, Prague, Czech Republic, 2Novartis Pharmaceuticals 
Corporation, Prague 3, Czech Republic, 3Charles University, Prague, Czech Republic
OBJECTIVES: Persistent high blood pressure is one of the leading causes of microal-
buminuria and progression of nephropathy in patients with type 2 diabetes. A large
number of studies have shown effective reduction of microalbuminuria after antihy-
pertensive therapy and reducing progression of nephropathy to end-stage renal disease 
(ESRD). In the AVOID study aliskiren once daily as an add-on therapy provide a sig-
niﬁ cant additional reduction in proteinuria compared to losartan alone. The objective
of this model was to evaluate a long-term cost-utility of the two strategies. METHODS:
AVOID was a multinational, randomized, double-blind study to evaluate the possible
renoprotective effect of aliskiren in the primary endpoint – the change in the urinary
albumin to creatinine ratio (UACR) when added aliskiren to existing losartan and 
optimal antihypertensive therapy for six months in hypertensive patients with type 2 
diabetes and nephropathy. However the duration of this study was short to evaluate 
the incidence of ESRD. The AVOID cost-effectiveness Markov model is designed to 
estimate progression to ESRD using the primary endpoint of AVOID – superior reduc-
tion in UACR for aliskiren versus placebo – and project associated local costs and
clinical outcomes in Czech patients suffered by type 2 diabetes, hypertension and 
nephropathy. RESULTS: AVOID demonstrates that combination of aliskiren with
losartan showed systematically improved effectiveness compared with losartan 
alone. Effectiveness was expressed as QALY gained throughout the model time 
horizon. The incremental cost-effectiveness (ICER) of the aliskiren treatment in the
base case was below € 1027 per QALY gained and in the extended case improved
with real-life cost of dialysis and renal transplantation on cost-saving therapeutical
approach. CONCLUSIONS: Aliskiren once daily as add-on therapy to losartan is 
highly cost-effective option for hypertensive patients with type 2 diabetes and
nephropathy.
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INCREASED PATIENT THROUGHPUT AND REDUCTION IN 
LABORATORY STAFF AND LABOR INTENSITY WITH THE USE OF
REGADENOSON
Smalarz AM1, Denevich S2, Boulanger L1, Spaulding J3
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Abt Associates, Inc., Lexington, MA, 
USA, 3Astellas Pharma US, Inc., Deerﬁ eld, IL, USA
OBJECTIVES: Regadenoson is a vasodilating stress agent used in patients undergoing
myocardial perfusion imaging (MPI) for detection of coronary artery disease. Its rapid
injection administration and weight-independent dosing may result in shortened
administration time versus adenosine or dipyridamole. We assessed whether the use 
of regadenoson results in overall MPI reduction in lab personnel time and consequen-
tially increased patient throughput. METHODS: An economic model was developed 
comparing regadenoson versus adenosine and dipyridamole on MPI laboratory pro-
ductivity and patient throughput through reduction in administration time and staff 
labor. We developed a pharmacologic stress agent survey (n  19) to evaluate the labo-
ratory personnel time and patient throughput. The results of this survey were used to 
populate the model. We included the administration of stress agents and managing 
associated adverse events for MPI. We solicited key opinion leaders including nurses, 
nuclear technologists and cardiologists to complete this survey in April and May of 
2008. RESULTS: Laboratory efﬁ ciency is reliant in part upon medication characteris-
tics (e.g. different stress agent dose, administration time, use of rapid injection vs. 
